In Wound Care Market, Growth is Not Surprising

In Wound Care Market, Growth is Not Surprising

Wound care revenues grow faster than other med device categories due to the demand and the desire of healthcare providers to reduce hospital stays. So innovation is constant. New products were on display at the Society for Advanced Wound Care met in Las Vegas this month, and Kalorama Information was there to gather developments for an upcoming wound care report. Our most current report on this fast-growth field, Global Wound Care Markets, details the opportunity available in dozens of segments for this growing field.


IBM Watson Health and Quest Diagnostics’ Bid to Advance Clinical Sequencing Informatics

IBM Watson Health and Quest Diagnostics’ Bid to Advance Clinical Sequencing Informatics

With next-generation sequencing (NGS), research scientists and clinicians are provided abundant raw data, but also too often deficient analytics software also known as informatics. Vendor-specific sequencing informatics software has limited access to third-party research discoveries in genomics. Sequencing analytics already in the clinical field may struggle to remain current with quickly evolving understanding of the genomic, epigenomic and transcriptomic underpinnings in cancer.


What's The Big Deal About Gene Editing? Drug Development.

What's The Big Deal About Gene Editing?  Drug Development.

Gene editing technology is fueled by two things - the need for better, more effective drug development, and the creation of a new technology called CRISPR. The old way to attack disorders have included transplantation to replace hematopoietic stem cells or gene therapy yield normal copies of the affected gene in cells through expression. Now the focus is genomes. CRISPR systems offer tremendous flexibility and power, and are opening up opportunities. That opportunity, seen in the chart here, is most present in drug development.


Advances in Sequencing Could Transform the Clinical Autopsy

Next-generation sequencing (NGS) could provide additional insights and medical value to post-mortem examinations. The widely observed decline in autopsies is largely a result of the decline in disease-related autopsies, which represent the majority of all autopsies performed. The medical utility of autopsies related to disease particularly remain in question with declining reimbursement and family consent, but could be reevaluated with the addition of molecular technologies. With NGS, clinical post-mortem examinations stand to reveal more than ever regarding disease-related mortality. Post-mortem sequencing introduces a new paradigm to patient engagement with important ethical questions, but also represents a minimally tapped resource for family health and potentially even translational research.


Must Have vs. Nice-to-Have: Navigating Complementary and Companion Diagnostics Tests

The companion testing market opportunity reflects far more than the original concept of companion - those required, FDA-mandated test/therapeutic pairs. The increasing role of supportive tests should be part of companion IVD product development. But there are some keys to understanding the market and launching new test products. All roads, it would seem, lead to data from clinical studies that can validate usage.